You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AP24534

Showing 1 - 25 of 34
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)

Terminated
Has Results
  • Chronic Phase Chronic Myeloid Leukemia
  • Ponatinib 30 mg QD
  • +2 more
  • Bruxelles, Belgium
    Cliniques Universitaire Saint-Luc (Site 058)
Oct 28, 2021

Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer Trial in Aurora

Completed
Has Results
  • Adenocarcinoma of the Lung
  • +7 more
  • Aurora, Colorado
    University of Colorado Cancer Center
Jan 19, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 15, 2022

Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Ponatinib 15 MG Oral Tablet
  • Brno, Czechia
  • +6 more
Nov 30, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

Malignant Hepatobiliary Tumor Trial in Scottsdale (Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life

Completed
Has Results
  • Malignant Hepatobiliary Neoplasm
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Nov 10, 2020

Chronic Myeloid Leukemia (CML) Trial in Italy (Ponatinib 15mg QD, Ponatinib 30mg QD)

Not yet recruiting
  • Chronic Myeloid Leukemia (CML)
  • Ponatinib 15mg QD
  • Ponatinib 30mg QD
  • Cagliari, Italy
  • +12 more
Jan 31, 2021

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +5 more
  • Blinatumomab
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia Trial in Worldwide (Ponatinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Ph+ Acute Lymphoblastic Leukemia
  • St Leonards, New South Wales, Australia
  • +41 more
Jan 18, 2021

Malignant Tumor Trial in Ann Arbor, Columbus (ponatinib HCl, laboratory biomarker analysis)

Unknown status
  • Malignant Neoplasm
  • ponatinib hydrochloride
  • laboratory biomarker analysis
  • Ann Arbor, Michigan
  • +1 more
Feb 14, 2020

Leukemia Trial in Houston (Ponatinib)

Terminated
Has Results
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 16, 2019

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in China (Ponatinib)

Recruiting
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Hefei, Anhui, China
  • +13 more
Aug 11, 2020

Myeloid Leukemia, Chronic, Chronic Phase Trial in Worldwide (Ponatinib)

Active, not recruiting
Has Results
  • Myeloid Leukemia, Chronic, Chronic Phase
  • Atlanta, Georgia
  • +85 more
Jan 4, 2022

Vascular Occlusive Events Associated With ICLUSIG®

Terminated
  • Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
    • Hackensack, New Jersey
    • +1 more
    Oct 30, 2020

    Chronic Myelogenous Leukemia, Hematologic Malignancies Trial in United States (Ponatinib)

    Completed
    • Chronic Myelogenous Leukemia
    • Hematologic Malignancies
    • San Francisco, California
    • +4 more
    May 15, 2018

    Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Portland (drug, device, biological)

    Completed
    • Acute Lymphoblastic Leukemia
    • Acute Myeloid Leukemia
    • Portland, Oregon
      OHSU Knight Cancer Institute
    May 21, 2020

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Trial in Israel, United States (Blinatumomab,

    Recruiting
    • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    • Blinatumomab
    • +10 more
    • Anchorage, Alaska
    • +152 more
    Aug 11, 2022

    Diabetes, Type 2 Trial in Worldwide (Vildagliptin, Metformin, Placebo)

    Completed
    • Diabetes Mellitus, Type 2
    • Buenos Aires, Santa Fe, Argentina
    • +186 more
    Dec 17, 2020

    GIST Trial in Boston, Portland, Philadelphia (Ponatinib)

    Completed
    Has Results
    • GIST
    • Boston, Massachusetts
    • +3 more
    Apr 17, 2018

    Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Trial in United States

    Approved for marketing
    • Chronic Myeloid Leukemia (CML)
    • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    • La Jolla, California
    • +32 more
    Feb 5, 2018

    Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome Trial (Ponatinib, 5-azacytidine,

    Withdrawn
    • Leukemia
    • +2 more
    • (no location specified)
    Jun 1, 2017

    Acute Myeloid Lukemia Trial in France (Ponatinib and Cytarabine)

    Active, not recruiting
    • Acute Myeloid Lukemia
    • Ponatinib and Cytarabine
    • Aix-en-Provence, France
    • +36 more
    Aug 6, 2020